ISB News

ISB’s Qiang Tian Receives UW Promotion to Affiliate Associate Professor

ISB senior research scientist Qiang Tian has received a promotion at the University of Washington to Affiliate Associate Professor.

June 29, 2015 – Congratulations to Qiang Tian, MD, PhD, ISB senior research scientist and head of the Cancer and Stem Cell Group (Hood Lab), who has received a promotion to Affiliate Associate Professor at the University of Washington’s Department of Medicine. Dr. Tian has been an Affiliate Assistant Professor since 2008 and has collaborated on research projects and grants, as well as led grand rounds and held faculty seminars. The promotion to Affiliate Associate Professor is effective July 1, 2015.

More on Dr. Tian’s bio and research: ISB Gets $2.3 million NIH Grant to Use Single-Cell Technology to Fight Cancer

Recent Articles

  • Timing is Everything: ISB Study Finds Link Between Bowel Movement Frequency and Overall Health

    Everybody poops, but not every day. An ISB-led research team examined the clinical, lifestyle, and multi-omic data of more than 1,400 healthy adults. How often people poop, they found, can have a large influence on one’s physiology and health.

  • Wei Wei, PhD

    Dr. Wei Wei Promoted to Associate Professor

    Wei Wei, PhD – an accomplished cancer researcher with expertise in biotechnology and cancer systems biology – has been promoted to ISB associate professor. The Wei Lab focuses on understanding how cancer cells adapt to therapeutic treatment to foster therapy resistance by coordinating their internal molecular machinery and how these adaptive changes evolve within diverse tumors influenced by the tumor microenvironment. 

  • Drs. Nitin Baliga and James Park

    How Glioblastoma Resists Treatment – and Ways to Prevent It

    Glioblastoma is one of the deadliest and most aggressive forms of primary brain cancer in adults and is known for its ability to resist treatment and to recur. ISB researchers have made breakthrough discoveries in understanding the mechanisms behind acquired resistance, focusing on a rare and stubborn group of cells within tumors called glioma stem-like cells.